These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11716139)

  • 1. Morphine in tardive and idiopathic dystonia (short communication).
    Berg D; Becker G; Naumann M; Reiners K
    J Neural Transm (Vienna); 2001; 108(8-9):1035-41. PubMed ID: 11716139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 5. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin.
    Pacchetti C; Albani G; Martignoni E; Godi L; Alfonsi E; Nappi G
    Mov Disord; 1995 May; 10(3):333-6. PubMed ID: 7651452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica.
    Berg D; Becker G; Reiners K
    J Neural Transm (Vienna); 1999; 106(7-8):725-8. PubMed ID: 10907730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
    Luquin MR; Scipioni O; Vaamonde J; Gershanik O; Obeso JA
    Mov Disord; 1992; 7(2):117-24. PubMed ID: 1350058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dystonia in Parkinson's disease: clinical and pharmacological features.
    Poewe WH; Lees AJ; Stern GM
    Ann Neurol; 1988 Jan; 23(1):73-8. PubMed ID: 3345068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tiapride in levodopa-induced involuntary movements.
    Lees AJ; Lander CM; Stern GM
    J Neurol Neurosurg Psychiatry; 1979 Apr; 42(4):380-3. PubMed ID: 458486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tardive dyskinesia in dopa-responsive dystonia: a reappraisal of the dopamine hypothesis of tardive dyskinesia.
    de la Fuente-Fernández R
    Neurology; 1998 Apr; 50(4):1134-5. PubMed ID: 9566407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Bathien N; Rondot P; Koutlidis RM
    J Physiol (Paris); 1981 Apr; 77(1):131-41. PubMed ID: 6112268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis.
    Trugman JM; Leadbetter R; Zalis ME; Burgdorf RO; Wooten GF
    Mov Disord; 1994 Jul; 9(4):441-6. PubMed ID: 7969212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
    Bezard E; Brotchie JM; Gross CE
    Nat Rev Neurosci; 2001 Aug; 2(8):577-88. PubMed ID: 11484001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 20. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Schelosky L; Poewe W
    Acta Neurol Scand Suppl; 1993; 146():46-9. PubMed ID: 8101415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.